Abstract
Urinary bladder carcinoma is estimated to be the ninth most common cause of cancer worldwide. The treatment of bladder carcinoma is an area of active research owing to lack of evidence of any treatment modality. Traditionally surgery, cystectomy, was considered the cornerstone of therapy. However, the morbidity of such approach has paved for bladder preservation approach with radiation in combination with chemotherapy. The use of transurethral resection of bladder tumor along with radiation and chemotherapy helps patients to have a functional bladder without compromising survival. Adjuvant radiation is an underutilized treatment modality. In the present era availability of sophisticated radiation technique allows delivery of radiation without increasing toxicity. Hence, adjuvant radiation may be used for patients with R1 resection and lymph node positive disease alone or in combination with chemotherapy. Radiation also appears a valuable treatment option for palliation in bladder tumor. We herein intend to review the present place of radiation in the management of transitional cell carcinoma of urinary bladder.
Keywords: Bladder carcinoma, chemo-radiotherapy, locally advanced.
Current Cancer Therapy Reviews
Title:Radiotherapy in Transitional Cell Carcinoma of Urinary Bladder Cancer –Where Does it Fit Into Treatment Protocol
Volume: 11 Issue: 2
Author(s): Rony Benson, Supriya Mallick, K.P. Haresh, P.K. Julka and G.K. Rath
Affiliation:
Keywords: Bladder carcinoma, chemo-radiotherapy, locally advanced.
Abstract: Urinary bladder carcinoma is estimated to be the ninth most common cause of cancer worldwide. The treatment of bladder carcinoma is an area of active research owing to lack of evidence of any treatment modality. Traditionally surgery, cystectomy, was considered the cornerstone of therapy. However, the morbidity of such approach has paved for bladder preservation approach with radiation in combination with chemotherapy. The use of transurethral resection of bladder tumor along with radiation and chemotherapy helps patients to have a functional bladder without compromising survival. Adjuvant radiation is an underutilized treatment modality. In the present era availability of sophisticated radiation technique allows delivery of radiation without increasing toxicity. Hence, adjuvant radiation may be used for patients with R1 resection and lymph node positive disease alone or in combination with chemotherapy. Radiation also appears a valuable treatment option for palliation in bladder tumor. We herein intend to review the present place of radiation in the management of transitional cell carcinoma of urinary bladder.
Export Options
About this article
Cite this article as:
Benson Rony, Mallick Supriya, Haresh K.P., Julka P.K. and Rath G.K., Radiotherapy in Transitional Cell Carcinoma of Urinary Bladder Cancer –Where Does it Fit Into Treatment Protocol, Current Cancer Therapy Reviews 2015; 11 (2) . https://dx.doi.org/10.2174/1573394711666151022203201
DOI https://dx.doi.org/10.2174/1573394711666151022203201 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Medicinal Chemistry and Anti-Inflammatory Activity of Nitric Oxide-Releasing NSAI Drugs
Mini-Reviews in Medicinal Chemistry Anti-cancer Peptides from Ras-P21 and P53 Proteins
Current Pharmaceutical Design Adhesion Dependent Signalling in the Tumour Microenvironment: The Future of Drug Targetting
Current Pharmaceutical Design Targeting Translation for Treatment of Cancer - A Novel Role for IRES?
Current Cancer Drug Targets Nanovesicle Formulation Enhances Anti-inflammatory Property and Safe Use of Piroxicam
Pharmaceutical Nanotechnology Oncomirs: From Tumor Biology to Molecularly Targeted Anticancer Strategies
Mini-Reviews in Medicinal Chemistry Organ Preservation by the Association of Chemotherapy and Radiotherapy in Invasive Bladder Cancer
Current Drug Therapy E-Cadherin Upregulation as a Therapeutic Goal in Cancer Treatment
Mini-Reviews in Medicinal Chemistry Reducing the Burden of Diabetes Treatment: A Review of Low-cost Oral Hypoglycemic Medications
Current Diabetes Reviews Garlic-Derived Allyl Sulfides in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Effects of Tea Catechins on Inflammation-Related Cardiovascular Diseases
Current Immunology Reviews (Discontinued) The Impact of Tumor Physiology on Camptothecin-Based Drug Development
Current Medicinal Chemistry - Anti-Cancer Agents Pharmacological Activity of Natural Non-glycosylated Triterpenes
Mini-Reviews in Organic Chemistry Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy
Current Pharmaceutical Design New Approach to Cancer Therapy: The Application of Signal Transduction to Anti-Cancer Drug
Current Medicinal Chemistry - Anti-Cancer Agents Diagnosis and Management of Endocrine Hypertension in Children and Adolescents
Current Pharmaceutical Design Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Overview of Ribonucleotide Reductase Inhibitors: An Appealing Target in Anti-Tumour Therapy
Current Medicinal Chemistry Meitner-Auger Electron Emitters for Targeted Radionuclide Therapy: Mercury-197m/g and Antimony-119
Current Radiopharmaceuticals